The effect of ranitidine and cisapride on acid reflux and oesophageal motility was investigated in 18 patients with endoscopically verified erosive reflux oesophagitis. Each patient was treated with placebo, ranitidine (150 mg twice daily), and ranitidine (150 mg twice daily) plus cisapride (20 mg twice daily) in a double blind, double dummy, within subject, three way cross over design. Oesophageal acidity and motility were monitored under ambulatory conditions for 24 hours on the fourth day oftreatment, after a wash out period of 10 days during which patients received only antacids for relief of symptoms. Acid reflux was monitored by a pH electrode located 5 cm above the lower oesophageal sphincter. Intraoesophageal pressure was simultaneously recorded from four transducers placed 20, 15, 10, and 5 cm above the lower oesophageal sphincter. Upright reflux was three times higher than supine reflux (median (range) 13-3 (3 7-35 0)% v 3-7 (0-37-6)% of the time with pH<4*0, p<001, n=18). Compared with placebo, ranitidine decreased total reflux (from 10*0 (3.2-32.6)% to 6-4 (1.2-22-9)%, p<001), upright reflux (p<005), supine reflux (p<0001), and postprandial reflux (p<0-01), but did not affect oesophageal motility. The combination of ranitidine with cisapride further diminished the acid reflux found with ranitidine -that is, cisapride led to an additional reduction of total reflux (from 6*4 (1-2-22.9)% to 3-7 (1.0-12.7)%, p<001), supine reflux (p<0.05), and postprandial reflux (p<O05). Cisapride also reduced both the number (p<0-01) and duration (p<0. 
acidity and motility were monitored under ambulatory conditions for 24 hours on the fourth day oftreatment, after a wash out period of 10 days during which patients received only antacids for relief of symptoms. Acid reflux was monitored by a pH electrode located 5 cm above the lower oesophageal sphincter. Intraoesophageal pressure was simultaneously recorded from four transducers placed 20, 15, 10, and 5 cm above the lower oesophageal sphincter. Upright reflux was three times higher than supine reflux (median (range) 13-3 (3 7-35 0)% v 3-7 (0-37-6)% of the time with pH<4*0, p<001, n=18). Compared with placebo, ranitidine decreased total reflux (from 10*0 (3.2-32.6)% to 6-4 (1.2-22-9)%, p<001), upright reflux (p<005), supine reflux (p<0001), and postprandial reflux (p<0-01), but did not affect oesophageal motility. The combination of ranitidine with cisapride further diminished the acid reflux found with ranitidine -that is, cisapride led to an additional reduction of total reflux (from 6*4 (1-2-22.9)% to 3-7 (1.0-12.7)%, p<001), supine reflux (p<0.05), and postprandial reflux (p<O05). Cisapride also reduced both the number (p<0-01) and duration (p<0.05) of reflux episodes and significantly increased amplitude, duration, and propagation velocity of oesophageal contractions (p<0.05) but did not affect the number of contractions. The findings show that the 30% reduction of oesophageal acid exposure achieved by a conventional dose of ranitidine (150 mg twice daily) can be improved to more than 60% by combination with cisapride (20 mg twice daily). The cisapride induced increase in oesophageal contractile force and propagation velocity seems to enhance the clearance of gastrooesophageal reflux. Combination of a histamine H2 receptor antagonist with a prokinetic agent may therefore provide an alternative treatment for reflux oesophagitis.
(Gut 1993; 34: 1025-1031) Several factors are responsible for recurrent exposure of the distal oesophagus to gastric contents and the subsequent development of reflux oesophagitis.' Among these factors, a reduced basal tone2-7 and frequent episodes of inappropriate relaxation389 of the lower oesophageal sphincter are regarded as the most important. Other motor abnormalities of the oesophagus that may contribute to the development of reflux oesophagitis are diminished peristaltic pressure amplitude,"'0 shortened duration and slowed propagation of the contraction waves,5 reduced peristaltic frequency,41' and delayed oesophageal transit.'2 The importance of delayed gastric emptying in the pathogenesis ofreflux oesophagitis is still controversial.- '18 Inhibition ofgastric acid secretion has become the traditional medical treatment for reflux oesophagitis. The healing rates achieved by a six to eight week treatment of erosive reflux oesophagitis are about 50% for potent histamine H2 receptor antagonists (for example, ranitidine (150-300 mg twice daily)'9) and up to 90% for omeprazole, a proton pump inhibitor.'0 21 Although these drugs are effective, they do not reduce the reflux of other gastric contents (pepsin, bile) and they do not modify the underlying causes of the disease by restoring lower oesophageal sphincter pressure or improving oesophageal clearance and gastric emptying. The newest prokinetic agent, cisapride, a cholinomimetic drug, has been shown to improve function of the lower oesophageal sphincter and to improve oesophageal and gastric clearance." Also, cisapride produces healing rates of up to 50% in erosive oesophagitis that are comparable with histamine H2 receptor antagonists.""8 As cisapride and histamine H2 receptor antagonists exert their effects by affecting different mechanisms, they may have an additive effect and produce higher healing rates than either medication alone. Ifthis is the case, the combination of cisapride and ranitidine should produce a greater diminution in oesophageal exposure to acid than ranitidine alone.
This hypothesis was tested in patients with confirmed reflux oesophagitis by performing 24 24 hour recording of intraoesophageal pH and pressure was started. At 0915, all patients ingested their study medication and received a standard breakfast (bread, butter, marmalade, and coffee, tea, or milk). At 1200, a standardised lunch was served consisting of lasagna (baked layers of noodles, meat, cheese, and tomato sauce), bread, salad, and cake for dessert. At 1600, the patients received a snack (tea or coffee with cake), and at 1800, a standard dinner was served (Swiss style muesli, consisting of cereals, milk, yogurt, fresh fruits). Identical meals were prepared for each study day and they were eaten within 30 minutes of serving. Free access to water was allowed. Smoking was permitted but the number and timing of cigarettes were noted on a diary sheet and had to be similar on all study days. During the study days, the patients were fully ambulatory and could follow their preferred daily routine except that they had to return to the laboratory for their meals. After dinner, each patient returned home. The times of retiring and getting up on the next morning were noted on the diary sheet and marked electronically by pushing the appropriate buttons on the recording unit. At 0800 on the next morning, the patients returned to the laboratory and shortly after 0900, the probes and recording equipment were removed.
PROBES AND PLACEMENT
A combined glass electrode (Ingold LOT 440-M4, Ingold Messtechnik AG, CH-8902 Urdorf, Switzerland) was used for intraoesophageal pH monitoring. Before and after each recording, the probe was standardised against buffer solutions at pH 1-7 and 7-0. The drift found after the 33 36 37 showed good correlation.
To measure acid reflux, several parameters were used38: (1) total reflux time (min), defined as the time with an intraoesophageal pH <4 0; (2) total reflux time (%), defined as the total time with an intraoesophageal pH <4-0 expressed as a percentage of the analysed period; (3) reflux episodes >6 s, defined as the number of episodes with an intraoesophageal pH <4-0 lasting longer than 6 s; (4) reflux episodes >5 min, defined as the number ofepisodes with an intraoesophageal pH <4-0 lasting longer than 5 min; (5) mean reflux duration (min), defined as the mean duration ofall reflux episodes; (6) maximal reflux duration (min), defined as the longest single reflux episode.
To measure oesophageal body motility, variables measured were32: (1) amplitude of contraction (mm Hg), defined as the difference between the baseline pressure and the maximal pressure during the pressure event; (2) duration of contraction (s), defined as the time elapsed between .0 the start and the end of the pressure event; (3) area under the pressure curve (mm Hgxs), calculated from the sum of all pressure values between the start and the end of the pressure event, multiplied by the sampling interval; (4) propagation velocity (cm/s), defined as the speed of a contraction and calculated from the delay time and the distance between the sensors; (5) contractility (mm Hg/s), defined as the maximal increment between consecutive pressure values divided by the sampling interval; (6) total contractions (no/24 h), defined as pressure curves that are not rejected as artifacts; (7) Table I ). Ranitidine reduced both upright and supine reflux and an additional reduction of supine reflux was produced by the combination with cisapride.
The highest values for oesophageal exposure to acid were found during the postprandial periods (Table II) . Ranitidine diminished the postprandial reflux found after breakfast and lunch but had no effect on postprandial reflux after dinner. The addition of cisapride led to a further reduction of postprandial reflux after lunch.
Whereas ranitidine only slightly decreased the number and duration of reflux episodes, the combination of ranitidine plus cisapride reduced the number and maximal duration of reflux episodes during the 24 h, upright, supine, and postprandial periods after breakfast and lunch (Fig 3 (A and B) , Tables I and II) . , p<0-05). Compared with the proximal oesophagus, the median duration of oesophageal contractions (p<0-05) and the median area under the pressure curve (p<0-05) were also higher in the distal oesophagus. The total number and the number of propagated and non-propagated contractions were two to four times higher during the upright than the supine period (p<O0 001). Propagated contractions were more often recorded in the proximal oesophagus (p<005), whereas non-propagated contractions occurred about twice as often in the distal as in the proximal oesophagus (p<0001).
Ranitidine did not affect oesophageal motility. Compared with ranitidine, the addition of cisapride led to an increase of contraction amplitude during the upright period (from 28- [3] [4] [5] [6] (3(0-444) s, p<005) . A cisapride induced increase in the area under the pressure curve was found during the 24 h period (Table III) and the postprandial periods after breakfast (from mm Hgxs to 550 mm Hgxs, p<00S) and lunch (from 37-5 (21-103) mm Hgxs to 505 (23-81) mm Hgxs, p<005). These effects of cisapride were confined to the mid and distal oesophagus. Table III shows that cisapride further increased the propagation velocity of oesophageal contractions but had no significant effect on oesophageal contractility (slope of the contraction curve) or on the number of total, propagated, and nonpropagated contractions.
Discussion
This is the first study presenting 24 hour combined pH and four channel manometry of the oesophagus in patients with reflux oesophagitis. The most important and novel findings are that the combination of the histamine H2 receptor antagonist ranitidine and the prokinetic agent cisapride greatly reduced oesophageal exposure to acid, and the addition of a standard oral dose of cisapride increased amplitude, duration, and propagation velocity of oesophageal contractions compared with placebo and ranitidine alone.
In our study group of 18 patients who had endoscopically confirmed reflux oesophagitis, we found a total reflux time ranging from 3 2% to 32-6% in the absence of treatment (Fig 1) . Therefore, our patients represent the full range from slight to severe gastro-oesophageal reflux. Sixteen of our 18 patients had combined reflux (reflux occurring in upright and supine positions), a pattern that is closely related to the development of oesophagitis. 44 The highest reflux values were found during the postprandial periods (Table II) . This has been explained by an increased number of transient sphincter relaxations after a meal. 3 The overall reduction of acid reflux by ranitidine (50 mg twice daily) was about 30% (Fig 1) , which is comparable with the decrease found in other 24 hour oesophageal pH measurement studies.4"42 Although ranitidine reduced both daytime (upright) and nocturnal (supine) reflux, it led to a more pronounced decrease ofnocturnal reflux. During the postprandial periods, reduction of reflux was most pronounced after breakfast, less pronounced after lunch, and no effect was found after dinner (Table II) oesophagus has not been affected. As cisapride increased both contraction amplitude and duration, the significant increase found in the area under the pressure curve could be expected.
Our data extend the knowledge of the effects of cisapride on oesophageal motility. They confirm the reports from short term stationary manometry studies indicating an increase of contraction amplitude and duration after intravenous injection of cisapride.4749 By contrast with our study, the available data for oral cisapride do not suggest that cisapride affects characteristics of oesophageal contraction. These differences might be due to lower doses used in some of the studies,4950 short measurement periods after oral ingestion that might not have been sufficient to reach effective drug concentrations,4749 and the fact that we investigated oesophageal motility on day four of oral drug treatment.
Considering the controversial data on the effects of cisapride on characteristics of oesophageal contraction, the influence of the recording technique is another important point. In our study, the combination of ranitidine and cisapride led to an increase of propagation velocity as calculated from the propagation of the pressure wave over the four sensors located 20, 15, 10, and 5 cm above the lower oesophageal sphincter (Table III) . When two channel manometry was simulated by analysing only the recordings from two sensors (15 and 5 cm above the lower oesophageal sphincter), the significant increase of propagation velocity induced by cisapride could not be detected.5' Four channel rather than two channel manometry should therefore be used for reliable recording of oesophageal motility.
As expected, contraction frequency was considerably higher during the day. Propagated contractions, which are thought to be predominantly under voluntary control, were detected more often in the proximal oesophagus whereas non-propagated contractions prevailed in the mid and distal oesophagus. It has been suggested that the distal non-propagated contractions are incomplete secondary contractions induced by gastro-oesophageal reflux. The finding that their number is neither affected by ranitidine nor by cisapride treatment does not support this hypothesis.
Although the combination of cisapride and ranitidine significantly increased amplitude, duration, and propagation velocity of oesophageal contractions, the changes in oesophageal motility seem small when compared with the considerable reduction in acid reflux. Therefore additional effects of cisapride on gastro-oesophageal motility such as an improvement of lower oesophageal sphincter function4849 and an acceleration of gastric emptying'8 might contribute to the reduction in acid reflux. On the other hand, the increase found in the contractile force of the oesophageal body together with an accelerated propagation of the contraction waves may be responsible for the acceleration of acid clearance.
In conclusion, the combination of cisapride with ranitidine leads to a considerable and additional reduction in oesophageal acid exposure compared with that achieved by ranitidine alone. Combined treatment with a histamine H2 receptor antagonist such as ranitidine and a prokinetic agent such as cisapride is a promising alternative for medical treatment of reflux oesophagitis and should be further tested in clinical trials. 
